

Wifi: MarriottBonvoy\_Conference  
Password: Novavax2022

# WORLD VACCINE CONGRESS | WASHINGTON

22<sup>ND</sup> ANNUAL

18-21 April 2022

Marriott Marquis Washington, DC



## COVID & BEYOND

Reuniting experts.  
Sharing groundbreaking knowledge.  
Tackling the Pandemic. In-person.

[Visit Congress Website](#)

CREATED BY

SPARK SOMETHING  
**TERRAPINN** 

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meetings of their kind across the globe.

Following on from the global COVID-19 pandemic, World Vaccine Congress Washington will be back bringing together the most senior and informed Industry experts across the entire vaccine landscape, with key sessions on COVID-19 and those leading the fight against COVID-19.









It will be one of the first opportunities to [meet live in-person](#) with the most relevant executives from the vaccine and COVID community since the pandemic began, to share experiences, knowledge, learn and network with others who are working against the virus. We will also continue to cover main vaccine progress in:

**COVID, influenza and other respiratory diseases, Immune profiling, cancer immunotherapy, one health and veterinary vaccines, clinical development, manufacture, safety, market access, supply & logistics and a focus on many other newly infectious and chronic diseases.**

From basic research to commercial manufacture, this one meeting covers the whole vaccine value chain where science, government and manufacturers all come together to create ground-breaking progress. If you are involved in vaccines or new to it because of the pandemic, this is the most important meeting you will be part of in 2022.

Join us in April for the most up to date and keynote driven content around the pandemic so far!

# Our Scientific Advisory Board



# Agenda at-a-glance

## April 18: Pre-congress workshops

- Biodefence and preparedness
- Maternal immunization
- Vaccine Technology
- Antimicrobial resistance
- Antibodies in treating COVID and infectious diseases
- HIV

## April 19: Plenary

- All-day keynote plenary sessions
- Interactive roundtable discussions
- Evening drinks & ViE Awards Dinner

## April 20 & 21: Dedicated conference themes



## April 21 PM: Closing plenary session and close of congress

# Pre-Congress Workshops Monday April 18

10:00 AM – 5:00 PM

## BIODEFENCE

**The role of vaccines in preventing outbreaks, through natural causes or biothreats**

*It only takes natural outbreaks and bioterrorism attacks like the Ebola and anthrax to highlight the danger and fragile balance we live in. To ensure global and international security, important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments. Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.*

**10:00 Workshop leader opening remarks:**  
**Matthew Hepburn, MD**, Senior Advisor to the OSTP Director on Pandemic Preparedness, **White House Office of Science and Technology Policy**

**10:10 Preparing for Disease X – Biodefense Concepts to Get Ahead of the Next Biothreat**

## MATERNAL IMMUNITY

**New developments in maternal vaccines and updates in immunization**

*Maternal Immunisation has been a widely debated talking point due to the recent pandemic, and lessons learned from all aspects of vaccine development have been incorporated in routine administration and for new vaccines. Traditionally recommended vaccines for pregnant women, are influenza and tetanus, however with emerging diseases such as COVID, and re-emerging diseases such as RSV, how will vaccine development be effected in a post-pandemic world with limited data? This workshop will provide up to date key information on both current and new targets.*

**10:00 Workshop leader opening remarks:**  
**Dr Flor Munoz**, Associate Professor, **Baylor College of Medicine**

**10:10 Updates on safety data for maternal flu vaccination**  
**Dr Saad Omer**, Director, Yale Institute for Global Health, Professor of Medicine, **Yale School of Medicine**

## HIV

**Is an HIV vaccine needed? Status of therapies and vaccines**

*Why is it taking so long to develop a vaccine? A review and update on current vaccines, antivirals and bnAbs pipeline.*

**10:00 Workshop Leader Opening Remarks: Update on HIV vaccines, bnAbs, therapeutics**  
**Dr Mary Marovich**, Director of Vaccine Research Program, **NIAID, NIH**  
**10:10 How bNAbs evolution can be recapitulated to inform vaccine design**  
**Dr Cynthia A Derdeyn**, Professor, Department of Pathology and Laboratory Medicine, Assistant Dean for Faculty Affairs, School of Medicine, School of Medicine, **Emory Vaccine Center**

**10:30 Virus escape from bNAbs therapy**  
**Dr Rebecca M. Lynch**, Assistant Professor, Microbiology, Immunology and Tropical Medicine, **George Washington University**  
**10:50 Update on HVTN trials, SOSIP immunizations and adjuvants**  
**Dr Julie McElrath**, Principal Investigator and Director, HVTN Laboratory Center, Director, **Fred Hutch Cancer Research**

## ANTIMICROBIAL RESISTANCE

*Addressing AMR through Prevention*

**10:00 Workshop leader opening remarks**  
**Dr Leonard Friedland, MD**, VP, Scientific Affairs and Public Health, **GSK Vaccines**

**10:10 Vaccines as another strategy to reduce antibiotic resistance**  
**Dr Jim Wassil, COO**, **VaxCyte**

**10:40 Update on the development of veterinary vaccines to reduce antimicrobial resistance**  
**Dr Cyril Gay**, Senior National Program Leader, **Office of National Programs, USDA**

**11:10 Vaccines as an essential tool in the fight against Antimicrobial Resistance**  
**Dr Leonard Friedland, MD**, VP, Scientific Affairs and Public Health, **GSK Vaccines**

**11:30 How do we assess the value of vaccines for preventing AMR?**

# Pre-Congress Workshops Monday April 18

<p><b>Dr Andrew Kilanski</b>, Senior Director – Emerging Infectious Diseases, <b>IAVI</b></p> <p><b>10:40 Expanding the utility of biodefense vaccines</b>  <b>Daniel Wolfe</b>, Branch Chief, CBRN Vaccines, <b>Biomedical Advanced Research and Development Authority (BARDA)</b></p> <p><b>11:10 An integrated computational approach to medical countermeasure preparedness</b>  <b>Dr Chris Earnhart</b>, Chief Technology Officer, <b>JPEO-CBRND Enabling Biotechnologies (JPEO-CBRND-EB)</b></p> <p><b>11:40 Regulatory frameworks for the development of medical countermeasures</b>  <b>Katya Vert-Wong</b>, Vice-President of Research &amp; Development Operations, <b>Sabin Vaccine Institute</b></p> <p><b>12:10 Ensuring rapidly available vaccines in a pandemic or biothreat environment</b>  <b>Beth-Ann Coller</b>, Executive Director, Global Clinical Development, <b>Merck</b></p>	<p><b>10:35 Current status of vaccine development to prevent maternal cytomegalovirus infection</b>  <b>Dr Mark R. Schleiss</b>, Professor, Department of Pediatrics, Division of Infectious Diseases and Immunology, <b>Minnesota Medical School and Masonic Children's Hospital</b></p> <p><b>11:00 New update on vaccine safety systems (v-safe, VAERS, VSD) in surveillance of COVID vaccines in pregnant women</b>  <b>Pedro Moro</b>, Medical Epidemiologist, Immunization Safety Office, <b>CDC and Prevention</b></p> <p><b>11:25 Current update on Group B streptococcus vaccine development</b>  <b>Bengt Johansson Lindbom</b>, CSO, <b>MinervaX</b></p> <p><b>11:50 Ethics of maternal vaccination in a pandemic –</b>          -Addressing evidence gaps for vaccine use in pregnancy          - Ethical considerations regarding pregnancy-specific risk  <b>Anne Lyerly, MD, MA</b> Professor of Social Medicine at the University of North Carolina</p> <p><b>12:15 – 1:00 Strategies to improve maternal vaccination acceptance – acceptance for new emerging diseases</b>  <b>Panel: All speakers</b>          Invited: <b>Ajoke Sobanjo-ter Meulen</b>, Senior Program Officer, <b>BMGF</b></p>	<p><b>Center Vaccine and Infectious Diseases Division</b></p> <p><b>11:10 Lessons learned from Janssen’s ph3 HIV vaccine</b>  <b>Dr Frank Tomaka</b>, Senior Director, Global Clinical Development, HIV &amp; STI Vaccines, <b>Janssen</b></p> <p><b>11:30 New HIV vaccine trial using RNA technology between IAVI, Moderna, GWU</b>  <b>Dr Jacqueline Miller</b>, Senior Vice President, Therapeutic Area Head, Infectious Diseases, <b>Moderna</b></p> <p><b>11:50 Comfort break</b></p> <p><b>12:20 – 13:00 Panel with all speakers</b>  <b>Moderated by: Dr Cynthia A Derdeyn</b>, Professor, Department of Pathology and Laboratory Medicine, Assistant Dean for Faculty Affairs, School of Medicine, School of Medicine, <b>Emory Vaccine Center</b>  <b>Additional speaker: Dr Dan Barouch</b>, Director, Center for Virology and Vaccine Research, <b>BIDMC</b></p>	<p><b>Craig Roberts</b>, VP, Vaccines, Center for Observational and Real-World Evidence, <b>Merck</b></p> <p><i>Pipeline updates from biotech and industry – alternatives from antibiotics</i></p> <p><b>12:00 TB vaccines</b>  <b>Dr Ann Ginsberg</b>, Deputy Director, TB Vaccines, <b>Gates Foundation</b></p> <p><b>12:30 Bacterial Vaccine Polypeptides</b>  <b>Prof Terrence L. Stull, M.D., President and Founder</b> <b>BacVax, Inc.</b></p>
---	--	---	--

# Pre-Congress Workshops Monday April 18

## 1:00 – 2:00 Networking Lunch Break

**2:00 From Discovery to Phase 1 – how to develop and scale manufacturability for inactivated vaccines**

**Daniel Stoughton**, Program Officer, Vaccine Development, **NIH/NIAD**

**2:30 Alternate routes of delivery for vaccines in an outbreak – The utility of needle free vaccine administration**

**LTC Melinda J. Hamer**, Deputy Director, Operations, **Fort Detrick, USAMRDC**

**3:00 NIAID's gap filling preclinical services for vaccine development**

**Larry Wolfrain**, Chief, Vaccine Section, Office of Biodefense, Research Resources, and Translational Research (OBRTR), Division of Microbiology and Infectious Diseases (DMID), **NIAID**

**3:30 What disease outbreaks have taught us about health security**

**Jennifer Nuzzo**, Associate Professor, **Johns Hopkins Center for Health Security**

**Panel: All speakers**

### ANTIBODIES FOR INFECTIOUS DISEASES

Role of human mAbs for discovery, therapy, and vaccine acceleration

**2:00 Workshop leader opening remarks:**

**Dr Vu Truong**, CEO, **Aridis Pharmaceutical**

**2:00–2:30 Are mAbs the answer to the AMR healthcare crisis?**

**Dr Gerald Pier**, Professor of Medicine, **Brigham and Women's Hospital Harvard**

**2:30–3:30 mAbs in IDs with antiviral and antibacterial applications over the last 10 years**

**Moderator: Dr Vu Truong**, CEO, **Aridis Pharmaceutical**

**Dr Mark Esser**, Vice President, Microbial Sciences, R&D **BioPharmaceuticals, AstraZeneca**

**Dr Lisa Purcell**, VP, Microbiology and Virology, **Vir Biotechnology**

**Dr Alina Baum**, Director of Infectious Diseases, **Regeneron**

**Dr Laura Walker**, CSO, **Adagio Therapeutics**

**3:30–4:00 Fireside: How has the pandemic accelerated mAb production and manufacturing?**

**Moderator: Dr Larry Zeitlin**, President, **Mapp Biopharmaceutical**

### VACCINE TECHNOLOGY

Breakthrough vaccine technologies that could save us from the next pandemic

*This workshop focuses on recent advances and their application in providing protection against COVID-19 and Disease X.*

**Workshop leader opening remarks**

**Dr Wolfgang Leitner**, Chief, Innate Immunity Section, **NIH**

**2:00 What should a pandemic vaccine ideally need to look like?**

**Dr Keith Klugman**, Director of the Pneumonia, Meningitis, Neonatal Sepsis and Antimicrobial Resistance Programs, **Bill and Melinda Gates Foundation**

**2:30 Pandemic innovations and platforms**

- Use of adjuvants in new vaccines
- Emulsion adjuvants for pandemic response

**Dr Derek O'Hagan**, **GSK Vaccines**

- Innovative adjuvant technology to help protect the world against infectious diseases

**Rob Janssen**, **Dynavax Technologies**

**2:00 Vaccine efforts in *Acinetobacter baumannii***

**Dr Gregory J. Tobin**, President & CEO, **Biological Mimetics, Inc.**

**2:30 Update on the development of a *Klebsiella* and *Pseudomonas* vaccine**

**Shite Sebastian**, VP, Development Group, **Affinivax**

**3:00 The potential of vaccine microarray patches in preventing the burden of AMR**

**Dr Mateusz Hasso-Agopsowicz**, Technical Officer & Project Manager, Vaccine Product & Delivery Research Immunization, Vaccines and Biologicals (IVB), **WHO**

**3:30 - 4:45 Panel with all speakers**  
15 min Q&A for the speakers on the pipeline updates

30 minutes for policy discussion moderated by **John Billington**, **GSK**

# Pre-Congress Workshops Monday April 18

*Invited: Charles Heffernan, Director, CRB*

## **4:00–4:30 Maximizing drug benefit– Inhaled Abs for lung infections (COVID)**

**Dr Hasan Jafri, CMO, Aridis  
Pharmaceuticals**

## **4:30–5:00 Using antibodies as a prophylactic immunotherapy**

**Dr Flonza Isa, Associate Medical Director,  
Early Clinical Development, Regeneron**

## **3:15 Second generation vaccines**

- Immune response to VOC, and VOI including Omicron after 2 or 3 doses of UB-612 vaccine

**Dr Farshad Guirakhoo, CSO, Vaxxinity**

- mRNA vaccines for future pandemics

**TBC Lori Panther MD, MPH, VP  
Clinical Development, Infectious  
Diseases, Moderna**

- Role of vector vaccines, boosters

**Dr Macaya Douoguih, Janssen**

- Clover’s adjuvanted protein-based vaccine: efficacy against SARS-CoV-2 variants and duration of protection

**Igor Smolenov, SVP, Global Clinical  
Development, Clover  
biopharmaceuticals**

## **4:30 Tools to enhance pandemic vaccine development**

- ACROBiosystems Journey in Engineering Recombinant Proteins for Vaccine and Therapeutic Research, Development, and Clinical Translation

**Nicholas Abuid, ACROBiosystems**

- New enzymatic DNA synthesis tool for commonly used vectors

**Dr Nasir Bashiruddin, CTO, OriCiro  
Genomics, Inc.**



# Pre-Congress Workshops Monday April 18

5:00 Chair Closing Remarks & End of Workshops

# Plenary Day 1, Tuesday April 19

## MORNING PLENARIES

8:30 Chair's opening remarks

**Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic**

8:45 **How long will our immunity against COVID last for and will our vaccines continue to work against VoCs?**

- How often will we need boosters?
- Our current understanding in longer term vaccine durability and efficacy
- The importance of and role in vaccinating children from COVID
- Infections rates and death rates after vaccinations
- How will the COVID variants impact our vaccines and public health?
- How will the FDA guide updates for Covid-19 vaccines as more data arises?

**Dr Nicole Doria-Rose, Chief of the Humoral Immunology Core, VRC, NIH**

**Dr Paul Burton, Chief Medical Officer, Moderna**

**Dr Gregory M. Glenn, MD, President, Research and Development, Novavax**

**Dr Hanneke Schuitemaker, VP, Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines**

**Dr Doran L. Fink, MD, Deputy Director – Clinical, Division of Vaccines and Related Products Applications, CBER, FDA**

9:45 **Preparations for Disease X – how do we keep the momentum going and learn from our experience?**

- What kind of global partnership do we need to achieve international vaccine deployment and fair access?
- Global strategy, alignment and local partnerships between all stakeholders
- Lessons learned with international deployment in outbreak regions
- Building global manufacturing capability
- Are we prepared for the next pandemic, what will Disease X be?
- Regulatory experience in dealing the time pressure of speed and safety

**Dr Jerome Kim, Director General, IVI**

**Dr Peter Hotez, Dean, National School of Tropical Medicine**

**Anuradha Gupta, Deputy CEO, GAVI Alliance**

**Dr Kirk Prutzman, Senior Advisor, Division of Vaccines, FDA**

**Dr Nicole Lurie, Director, CEPI**

**Dr David Kaslow, CSO PATH**

10:45 **Networking Coffee Break – Sponsored by**



## 11:40 INTERACTIVE ROUNDTABLES

**1. Impact of COVID vaccine work on research sites and what the future holds From a Site Perspective**

**Dr William Smith, Alliance for Multispecialty Research**

**2. Title TBC - Senior representative, PPD**

**3. Title TBC - Senior representative, Emergent BioSolutions**

**4. Five Ways COVID-19 Changed the Future of Protocol Design for Vaccine Development**

**Ghiorghis (George) Belai, Vice President, Global Strategy, FHI Clinical**

Recruiting speakers, contact

[wing-yun.cheung@terrapinn.com](mailto:wing-yun.cheung@terrapinn.com) For plenary, clinical and bioprocess talks

[nadia.konneh@terrapinn.com](mailto:nadia.konneh@terrapinn.com) For immune profiling, one health and veterinary

[lauren.sheppard@terrapinn.com](mailto:lauren.sheppard@terrapinn.com) For cancer immunotherapy, safety and market access

[abdu.kauroo@terrapinn.com](mailto:abdu.kauroo@terrapinn.com) For respiratory, emerging, partnerships

[Ellie.Whitehead@terrapinn.com](mailto:Ellie.Whitehead@terrapinn.com) For vaccine logistics and mAbs

# Plenary Day 1, Tuesday April 19

**Jon B. "Ben" Woods, MD, Senior Medical Advisor, FHI Clinical**

**5. Title TBC – ICON**

**6. Onsite PBMC processing to increase immunological response data in clinical trials**

**Steven Schmid, Clinical Trials of Texas**

**7. COVID vaccine hesitancy in minority communities; what have we learned from our front line doctors? A case study from New York – Senior representative, SOMOS**

**8. Challenges and Opportunities for Addressing Vaccine Hesitancy**

**Todd Wolynn, CEO & Cofounding Pediatrician, Kids Plus Pediatrics**

**9. Challenges with analytical characterization and rapid lot release of multivalent mRNA vaccines**

**Dr Gautam Sanyal, Principal Consultant and Founder, Vaccine Analytics, LLC**

**10. Discussion on patents: What are the real benefits and risks in removing patents in vaccine development?**

**Dan Stoughton – Program Officer, Vaccine development, NIH**

**Komal Kalha, Associate Director, IP and Trade Policy, IFPMA**

**11. Title TBC – Darin Seehafer, Executive Director, Vaccines and EID, Syneos Health & Lynlee Burton, Vice President, Clinical Development – Vaccines, Syneos Health**

**12. Title TBC – Senior representative, Ocugen**

**13. Title TBC – Lumacyte**

**14. Title TBC – 21Grams**

1:10 Networking Lunch (Exhibition Hall Floor 2)

2:00 POSTER & PANCAKES

Meet new scientists and young investigators with new data in the poster zone of the exhibition hall (Floor 2)

## AFTERNOON PLENARIES

**2:30 Vaccine Equity: Lessons from the COVID-19 Pandemic**

- The lack of a unified global response to the pandemic continues to present a barrier to global health, freedom of movement and economic recovery
- How can we ensure that vaccine equity is truly achieved in 2022, drawing the pandemic to a close?
- What lessons must we take forward, beyond this pandemic, to ensure equal and fair access to critical supplies – regardless of wealth or geography – when future black swan events emerge?

**Dr Mariangela Simao, Assistant Director General for Access to Vaccines, WHO**

**Jean-Cédric Meeùs, Chief Transport, UNICEF Supply Division**

**Anuradha Gupta, Deputy CEO, GAVI Alliance**

**Mike Bhaskaran, Chief Operating Officer of Logistics & Technology, DP World**

**Paula Pohja-Hutchinson, Global Policy Director COVID-19 vaccine, AstraZeneca**

**3:30 How will we tackle the lowering routine immunization rates going forward?**

- How do we catch-up on the declining immunization rates?
- How can re-imagine an immunization schedule with new vaccines?
- Strengthening the health, responsiveness and resilience of the vaccine ecosystem to deliver innovation to meet public health needs
- Lessons learned from the COVID-19 pandemic that can help improve global preparedness and security

**Dr Mitchell Wolfe, Chief Medical Officer, CDC**

**Dr David Kim, Director, Division of Vaccines, Assistant Secretary for Health, U.S. Department of Health and Human Services**

**Radife Kiral, Vaccines Regional President, North America, Pfizer**

**Hatice Küçük, Executive Director, The G20 Health and Development Partnership**

**Joanne Monahan, Senior Vice President, U.S. Vaccines Business Unit Lead, Merco**

**Judy Stewart, Senior Vice President, Head of US Vaccines, GSK**

Recruiting speakers, contact

[wing-yun.cheung@terrapinn.com](mailto:wing-yun.cheung@terrapinn.com) For plenary, clinical and bioprocess talks

[nadia.konneh@terrapinn.com](mailto:nadia.konneh@terrapinn.com) For immune profiling, one health and veterinary

[lauren.sheppard@terrapinn.com](mailto:lauren.sheppard@terrapinn.com) For cancer immunotherapy, safety and market access

[abdu.kauroo@terrapinn.com](mailto:abdu.kauroo@terrapinn.com) For respiratory, emerging, partnerships

[Ellie.Whitehead@terrapinn.com](mailto:Ellie.Whitehead@terrapinn.com) For vaccine logistics and mAbs

# Plenary Day 1, Tuesday April 19

4:30 Networking Coffee Break
5:00 Fireside chat: <b>How did CDC respond to COVID-19 and global vaccination?</b> <b>Interviewer: Dr Gregory A. Poland</b> , Director of Mayo Vaccine Research Group, <b>Mayo Clinic</b> <b>Dr Mitchell Wolfe</b> , Chief Medical Officer, <b>CDC</b> <b>Christa Capozzola</b> , Chief Financial Officer, <b>CDC</b> <b>Dr David Fitter</b> , Chief, Immunization Systems Branch, <b>CDC</b>
5:50 Chair's Closing Remarks and Close of Congress Day 1
6.40 Pre-Awards Networking Drinks Reception
7:30 <b>Gala Dinner &amp; 15<sup>th</sup> Annual ViE Awards Ceremony</b>

**The ViE awards are now open for nominations and voting! Winners will be announced during the Gala Dinner evening of April 19th**



On April 20 - 21, see from pg 13 -37 for the dedicated co-conferences.

## Afternoon of April 21

### DAY 3 AFTERNOON PLENARY OF CONGRESS

1:30 Chair's opening remarks <b>Dr Gregory A. Poland</b> , Director of Mayo Vaccine Research Group, <b>Mayo Clinic</b>
1:40 <b>Safety and efficacy for children – should we be vaccinating them against COVID and is it working?</b> <b>Dr James D. Campbell, MD, MS</b> , Professor, Department of Pediatrics, Division of Infectious Diseases and Tropical Pediatrics, <b>University of Maryland School of Medicine, Center for Vaccine Development and Global Health</b>
2:10 <b>Status on vaccinating maternal COVID &amp; RSV vaccine approaches</b> <b>Dr Saad Omer</b> , Director, Yale Institute for Global Health, Professor of Medicine, <b>Yale School of Medicine</b>
2:40 <b>Pan-corona and universal vaccines – is this our way forward out of a pandemic and is it feasible to make one in time?</b> <b>Dr Kayvon Modjarrad</b> , Director, Emerging Infectious Diseases Branch, <b>Walter Reed Army Institute of Research</b> <b>Dr Sriram Sathy</b> , CSO, <b>Codiak Bio</b> <b>Dr Mark Newman</b> , CSO, <b>GeoVax</b> <b>Dr Maria Elena Bottazzi</b> , Associate Dean, National School of Tropical Medicine & Co-Section Head, <b>Paediatric Tropical Medicine</b>
<b>3:30 Chair Closing Remarks and End of Congress</b>

Recruiting speakers, contact

[wing-yun.cheung@terrapinn.com](mailto:wing-yun.cheung@terrapinn.com) For plenary, clinical and bioprocess talks  
[nadia.konneh@terrapinn.com](mailto:nadia.konneh@terrapinn.com) For immune profiling, one health and veterinary  
[lauren.sheppard@terrapinn.com](mailto:lauren.sheppard@terrapinn.com) For cancer immunotherapy, safety and market access  
[abdu.kauroo@terrapinn.com](mailto:abdu.kauroo@terrapinn.com) For respiratory, emerging, partnerships  
[Ellie.Whitehead@terrapinn.com](mailto:Ellie.Whitehead@terrapinn.com) For vaccine logistics and mAbs

# Plenary Day 3, April 21

Wednesday April 20, 2022 COVID & Beyond, Day 2

9:00 Chair's opening remarks <b>Dr Philip Krause, Former Deputy Director, CBER, FDA</b>
<b>Current COVID Vaccines</b>
9:10 <b>COVID-19 – where are we with vaccines, variants and boosters?</b> <ul style="list-style-type: none"><li>• What do we mean by protection? What does the future hold?</li><li>• Consideration of annual immunization boosters</li><li>• Variants of concern</li><li>• Durability of protection</li><li>• Protecting susceptible populations</li><li>• Immunization of adolescents and pediatric populations</li><li>• Hesitancy</li></ul>
9:25 <b>Panel: Cross cutting activities to enable vaccine development</b> <ul style="list-style-type: none"><li>• Designing a network of collaborative laboratories focusing on SARS CoV-2 and further pathogens</li><li>• Harmonization of protocols and reagents for immunological measurement across various laboratories worldwide</li></ul> <b>Dr Valentina Bernasconi, Scientist and Project Leader, CEPI</b> <b>Dr Jenny Hendriks, Head Department of Viral Vaccines Biomarker, Janssen</b> <b>Dr Ivana Knezevic, Scientist, Team Leader, WHO</b>
<b>Longer term data &amp; updates from:</b>
10:10 <b>AstraZeneca/Oxford University</b> <b>Dr Prakash Bhuyan, MD, Vice President, Head of Infectious Diseases, Clinical Development, AstraZeneca</b>
10:25 <b>Moderna's COVID vaccine: An update on child vaccinations, CoVs and durability</b> <b>Dr Randall Hyer, Head of Global Medical Affairs, Moderna</b>
10:40 Networking Coffee Break
11:40 <b>Clinical Update on Novavax' Recombinant Nanoparticle Protein Subunit COVID-19 Vaccine as a Booster</b> <b>Dr Gregory M. Glenn, MD, President, Research and Development, Novavax</b>
11:55 <b>Update on Janssen's COVID-19 vaccine efforts</b> <b>Dr Hanneke Schuitemaker, VP, Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines</b>
12:10 <b>Title TBC</b> <b>Jaime Hernandez, MD, FACP, FIDSA, Executive Medical Director, Clinical Development, Syneos Health</b>
<b>Pipeline Updates</b>
12:40 <b>Clinical evaluation of Ad5 viral vector based COVID-19 vaccine immunization via inhaled delivery route</b> <b>Dr Xuefeng Yu, CEO, CanSino Biologics Inc.</b>
1:10 Networking Lunch & Poster Session
2:40 <b>Update on Medicago's plant-based COVID VLP vaccine program</b> <b>Senior Medical Affairs Representative, Medicago</b>
3:10 <b>COVAXIN™ (BBV152) update</b> <b>Dr Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen</b>
<b>Next Generation COVID vaccines</b>
3:55 <b>Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination</b>

Recruiting speakers, contact


[wing-yun.cheung@terrapinn.com](mailto:wing-yun.cheung@terrapinn.com) For plenary, clinical and bioprocess talks

[nadia.konneh@terrapinn.com](mailto:nadia.konneh@terrapinn.com) For immune profiling, one health and veterinary

[lauren.sheppard@terrapinn.com](mailto:lauren.sheppard@terrapinn.com) For cancer immunotherapy, safety and market access

[abdu.kauroo@terrapinn.com](mailto:abdu.kauroo@terrapinn.com) For respiratory, emerging, partnerships

[Ellie.Whitehead@terrapinn.com](mailto:Ellie.Whitehead@terrapinn.com) For vaccine logistics and mAbs

<p><b>Dr Sean Tucker, Chief Scientific Officer, Vaxart</b></p>	
<p>4:10 Networking Coffee Break – Sponsored</p>	<p><b>CRODA</b></p> <p>by Croda</p>
<p>4:40 Successful Execution of a Phase III COVID-19 Vaccine Clinical Trial  <b>Dr Riaan van Tonder, Vice President, Global Delivery, Accelerated Enrollment Solutions (AES)</b></p>	
<p>5:10 Recombinant COVID vaccine program  <b>Dr Roman Chicz, Global Project Head, COVID, Sanofi Pasteur</b></p>	
<p>5:40 NCI’s mucosal nanoparticle COVID-19 vaccine to boost respiratory immunity, increase protection and reduce transmission in primates  <b>Dr Jay A. Berzofsky, M.D., Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute</b></p>	
<p>6:10 Chair’s Closing Remarks and Close of Congress Day 2</p>	
<p>6:15 Off-site Networking Drinks, follow the congress team          Sponsored by</p>	
	

**Thursday April 21, 2022 COVID & Beyond, Day 3**

<p>9:00 Chair’s opening remarks  <b>Dr Philip Krause, Former Deputy Director, CBER, FDA</b></p>	
<p><b>Next Generation COVID vaccines</b></p>	
<p>9:10 What have we learnt from administering millions of COVID vaccines? – title TBC  <b>Senior representative, SOMOS</b></p>	
<p>9:40 Inovio’s DNA COVID vaccine update  <b>Dr Joseph Kim, CEO, Inovio</b></p>	
<p>10:10 Using a broad selection of virus-specific T cell epitopes to create new second and third generation vaccines against COVID  <b>Dr Mikkel W. Pedersen, Chief Scientific Officer, Vaccibody</b></p>	
<p>10:40 Networking Coffee Break</p>	
<p>11:30 Clinical update on AKS-452, a low cost, shelf-stable, Fc-fusion protein COVID vaccine  <b>Todd Zion, CEO, Akston Bio</b></p>	
<p>11:45 COVID program vs variants of concern  <b>Dr David Anderson, CSO, VBI Vaccines</b></p>	
<p>12:00 Supporting the development of viral vector and viral vaccine development for future COVID vaccines  <b>Reserved for FujiFilm Irvine</b></p>	
<p>12:15 Developing a Highly Conserved, Non-human-like, and Cross-reactive Peptide T cell Epitope COVID-19 Vaccine  <b>Dr Annie De Groot, Founder, CEO &amp; CSO, EpiVax Inc.</b></p>	

# WORLDVACCINE CONGRESS | COVID & BEYOND

12:30 Networking Lunch & Poster Session  
Plenary sessions resume at 1:30 – don't miss it!

9:00 Chair's opening remarks

**Dr Rafick-Pierre Sékaly**, Professor and Vice-Chair of Translational Medicine, Department of Pathology and Laboratory Medicine, **Emory University School of Medicine**

**Keynotes**

9:10 **Panel- Immune Profiling: Lessons learned from the coronavirus pandemic to help inform future vaccine development**

- What have we learnt from monitoring the immune responses to SARS-CoV-2 vaccines in different populations?
- How can this help inform future vaccine development?
- Why did the majority of mRNA vaccines work so well? What research has been done to understand the efficacy of these vaccines?

Moderator: **Dr Rafick-Pierre Sékaly**, Professor and Vice-Chair of Translational Medicine, Department of Pathology and Laboratory Medicine, **Emory University School of Medicine**

**Dr Alessandro Sette**, Center Head, Division Head, and Professor Center for Infectious Disease, **LaJolla Institute**

**Dr Ofer Levy**, Director, Precision Vaccines Program, Division of Infectious Diseases, **Boston Children's Hospital**, Professor, **Harvard Medical School**

**Dr Sharon Benzeno**, Chief Business Development Officer, **Adaptive Biotechnologies**

**Dr Rolando Pajon**, Head of Respiratory Vaccines, Clinical Biomarkers, **Moderna Therapeutics**

10:10 **Combining systems biology with artificial intelligence to understand the human immune system, and provide effective vaccines for all populations**

**Dr Wayne Koff**, President and CEO, **Human Vaccines Project**

10:40 Networking Coffee Break

11:40 **Advances in the technologies used to study human B-cell repertoires**

**Dr James Crowe**, Director, **Vanderbilt Vaccine Center**

**Precision Vaccinology: Targeting Vulnerable Populations**

12:10 **Transcriptomic signatures of humoral response to high dose influenza and adjuvanted influenza vaccine in the elderly population**

**Prof Inna G. Ovsyannikova**, Lab Director, Mayo Vaccine Research Group, **Mayo Clinic College of Medicine**

12:40 **Age-associated alterations in platelet function: Effects of influenza vaccination**

**Dr Albert Shaw**, Professor of Medicine, Infectious Disease, **Yale School of Medicine**

1:10 Networking Lunch & Poster Session

2:40 **Determining the impact of COVID-19 mRNA vaccines in individuals with autoimmunity**

**Dr Jane Buckner**, President, **Benaroya Research Institute at Virginia Mason**

**Immune System Characterization & Big Data**

3:10 **Systems vaccinology enabled by multiomic single cell immune profiling**

**Dr Rea Dabelic**, Market Development Manager, Immunology, **10x Genomics**

3:40 **T-cell Immune Response: Exploring emerging themes in vaccine development and COVID-19 variants**

**Dr Patrick Raber**, Director, Business Development, **Adaptive Biotechnologies**

4:10 Networking Coffee Break – Sponsored by Croda

**CRODA**

4:40 Immune Monitoring through Single-Cell Functional Proteomics Reveals Polyfunctional “Supervillain” Cells Driving Mechanisms of Severe Inflammation and Post-Acute Sequelae of COVID-19

Senior representative, IsoPlexis

5:10 The new xMAP® INTELLIFLEX; A rich history of enabling ground-breaking research

Senior representative, Luminex Corporation

5:25 Rapid COVID assays and diagnostics

5:40 Adaptive immune responses to SARS-CoV-2

Dr Alessandro Sette, Center Head, Division Head, and Professor Center for Infectious Disease, La Jolla Institute

6:10 Chair’s Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Sponsored by



**Thursday April 21, 2022 Immune Profiling Conference, Day 3**

9:00 Chair’s opening remarks

Prof Inna G. Ovsyannikova, Lab Director, Mayo Vaccine Research Group, Mayo Clinic College of Medicine

**Immune Profiling Techniques to Advance Rational Vaccine Design**

9:10 Panel: How can we use immune profiling platforms & big data to inform next generation vaccines?

- Exploring how we can use bioinformatics, data science and computational vaccinology to help drive vaccine product and technology platform development
- How do we evaluate large datasets required to translate complex outputs into actionable insights?
- Looking beyond single studies: Discussing the challenges of integrating data across studies

Dr Robert van den Berg, Head Data Sciences & Computational Vaccinology, GSK

Dr Konstantin Zeldovich, Deputy Director, Computational Sciences, Sanofi

Dr Wei Zheng, Director of Computational Science, Moderna

10:10 Using systems immunology to understand responses to vaccination

Dr Amy Chung, Laboratory Head, Department of Microbiology and Immunology (DMI), The Peter Doherty Institute for Infection and Immunity

10:40 Networking Coffee Break

11:30 Applying Systems serology/novel omics platforms to profile antibodies generated in response to vaccines

12:00 Application of molecular engineering tools and quantitative analysis to the development of immunotherapeutics and vaccines

- Developing high throughput tools to evaluate the antibody response in disease states ranging from infection to cancer, to aid in therapeutic antibody and vaccine design & development

12:30 Networking Lunch & Poster Session  
Plenary sessions resume at 1:30 – don't miss it!

# WORLDVACCINE CONGRESS | CANCER & IMMUNOTHERAPY

Official Manufacturing Partner



Wednesday April 20, 2022 Cancer & Immunotherapy Vaccines Conference, Day 2

9:00 Chair's opening remarks: [Dr Lauren Wood, CMO, PDS Biotech](#)

## Precision oncology

09:10 **Keynote panel: Advances in precision medicine tools informing strategies for mono & combination therapies**

- Ongoing challenges for precision oncology;
  - Tumor heterogeneity, diverse resistance mechanisms
- Incorporating AI and machine learning tools into clinical oncology
- Implementation of novel biomarker strategies – epigenetic, alternative splicing, microbiome
- Progress made in precision medicine enabled oncology drug development

**Moderator: [Dr Laura E. Benjamin, CEO & President, OncXerna](#)**

**[Dr Roy Baynes, SVP, Global Clinical Development & Chief Medical Officer, Merck Research Laboratories](#)**

**[Dr Axel Hoos, CEO, Scorpion Therapeutics](#)**

**[Dr Michael Kalos, Managing Director, Next Pillar Consulting](#)**

10:10 **Clinical development of Cosibelimab as a monotherapy & in combination**

***Invited: [Checkpoint Therapeutics](#)***

10:40 Networking Coffee Break

## Cancer vaccines, immunotherapies & oncolytic viruses

11:40 **Novel Vaccinia Enhanced Template (VET) oncolytic platform**

**[Dr Steven Thorne, CSO, Kalivir Therapeutics](#)**

12:10 **Development of CodaLytic™ oncolytic virus for the treatment of triple negative breast cancer**

**[Dr Johanna Kaufmann, Executive Vice President, Oncology, Codagenix](#)**

12:40 **Clinical development of oncolytic virus therapies using Vesicular Stomatitis Virus (VSV) platform**

***Invited: [Dr Miguel Munoz-Alia, Scientific Director, Paramyxovirus Engineering, Vyrriad Inc](#)***

1:10 Networking Lunch & Poster Session

2:40 TBC

**Reserved**

2:55 **Cancer vaccine delivery by precise intradermal administration**

**[Senior Representative, Kindeva Drug Delivery](#)**

3:10 **PV-001 - a novel combination immunotherapy leveraging the dengue virus adjuvant and an autologous dendritic cell therapy**

**[Tony Chen, CEO, PrimeVax Immuno-Oncology](#)**

3:40 TBC

4:10 Networking Coffee Break – Sponsored by Croda

## CRODA

4:40 **Developing an engineered exosome-based therapies platform for cancer and pan-beta coronavirus vaccine**  
**Dr Sriram Sathy, CSO, Codiak Bio**

5:10 **Panel: Advances in our understanding of the key parameters of tumor epitope immunogenicity**

- How diverse have neoantigen predictions remained across different groups?
- What characteristics or parameters are good predictors of immunogenicity?
  - Binding affinity & stability, tumor abundance
- How can neoantigen prediction be improved?
  - Model validations

**Moderator: Dr Daniel K Wells, Scientific Founder & SVP of Strategic Research, Immunai; Former TESLA Project Lead, Parker institute for Cancer Immunotherapy**

**Dr Praveen Aanur, Vice President, Therapeutic Area Head for Oncology, Moderna**

**Dr Timothy Wells, Research Scientist, Tisch Cancer Institute, Mount Sinai School of Medicine**

**Invited: Dr Jessica Flechtner, CSO, Genocea**

**Invited: Dr Gerald P. Linette, Professor Of Medicine, Center For Cellular Immunotherapies, University of Pennsylvania**

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Sponsored by

### Thursday April 21, 2022 Cancer & Immunotherapy Vaccines Conference, Day 3

9:00 Chair's opening remarks:

#### Nucleic Acid Based Immunotherapies

9:10 **mRNA approaches for Personalized Cancer Vaccines**

**Dr Robert Meehan, Senior Medical Director, Moderna Therapeutics**

9:40 **Quality Considerations for mRNA Vaccine Development**

**Khaled Yamout, Senior Director Quality Control, TriLink BioTechnologies**

10:10 **Clinical updates on autologous dendritic cell vaccines for solid tumors**

**Dr Bill Hearl, CEO, Immunomic Therapeutics**

10.25 **dbDNA - Enzymatic DNA driving innovation in Cancer treatment**

**Dr Lisa Caproni, Head of Vaccine Discovery, Touchlight**

10:40 Networking Coffee Break

11:30 **GT-EPIC platform to target advanced hepatocellular cancer in a patient specific manner**

**Dr Niranjani Sardesai, Founder, President & CEO, Director, Geneos Therapeutics**

12:00 **Development of mRNA based cancer vaccines using a fixed combination of shared antigens**

12:30 Networking Lunch & Poster Session  
 Plenary sessions resume at 1:30 – don't miss it!

# WORLDVACCINE

## CONGRESS | INFLUENZA & RESPIRATORY

Wednesday April 20, 2022 Influenza and Respiratory Vaccines, Day 2

9:00 Chair's opening remarks

**Jerald Sadoff**, Senior Advisor Vaccine Development, **Janssen**

### Developments in COVID-19 & Universal Influenza Vaccine

9:10 The effect of the flu season and other respiratory diseases coinciding with COVID – what have we learnt?

**Paula Barbosa**, Associate Director, Vaccine Policy, **IFPMA**

9:40 Universal flu update: are we any closer to finding the “holy grail”? The Grand Challenge

**Dr James Crowe**, Director, **Vanderbilt Vaccine Center**

10:10 Universal Influenza Vaccine Strategies

- Influenza as an ecological niche
- Human Influenza vaccine successes and failures
- Rhinovirus protecting against influenza may protect against SARS-CoV-2

**Dr Matthew J. Memoli**, Director, LID Clinical Studies Unit, Laboratory of Infectious Diseases, **NIAID, NIH**

10:40 Networking Coffee Break

### Respiratory Pathogens

11:40 Assessing Vaccine Efficacy for Existing and Emerging COVID variants

**Lisa Kierstead**, Executive Director, Vaccine Sciences, **PPD, part of Thermo Fisher Scientific**

12:10 SARS-CoV-2 Animal Models

**Konrad Stadler**, Chief Scientific Officer, **Viroclinics-DDL**

12:40 Update on Novavax' NanoFlu vaccine and COVID-19-NanoFlu Combination Vaccine development

**Dr Vivek Shinde**, Vice President, Clinical Development Lead, Older Adult Influenza & RSV Vaccines, **Novavax**

1:10 Networking Lunch & Poster Session

2:40 Practical considerations of vaccine delivery: how packaging choices impact supply and access

**Marie Liesse Le Corfec**, Portfolio & Product Marketing Director, **BD Medical - Pharmaceutical System**

**Daniel Smith**, Global Vaccination Director, **BD Medical - Medication Delivery Solution**

3:10 Next-generation Influenza Vaccines/Structural vaccinology for influenza virus

**Masaru Kanekiyo**, Chief, Molecular Immunoengineering Section, Vaccine Research Center, **NIH**

3:40 MERS – latest vaccine updates

**Prof Ab Osterhaus**, Director, **University of Veterinary Medicine Hannover**

4:10 Networking Coffee Break – Sponsored by Croda

# CRODA

4:40 Correlates of protection for FLU/Covid Assays

**Prof Emanuele Montomoli**, Professor at the **Public Health University of Siena & CSO, VisMederi**

4:55 Improving clinical efficacy of respiratory vaccine development

**Mark Emalfarb**, Chief Executive Officer, **Dyadic**

5:10 Mission Possible: Rock-solid in-vitro testing to conquer the vaccine development process

**Kari Roberts**, Business Development Manager, **Microbiologics**

5.25 Insights from near real-time data on infection rates and related outcomes in the post COVID-19 vaccine period

**Vikas Gupta**, Director, MMS Medical Affairs, **BD Insights Life Sciences**

# WORLDVACCINE

## CONGRESS | INFLUENZA & RESPIRATORY

**Kalvin Yu, Vice President, Medical & Scientific Affairs US Region, BD Medical**

**5:40 Clinical Development Update on OVX836 disruptive T-cell vaccine for broad-protection against multiple influenza strains**

**Senior representative, Osivax**

**5:55 Predicting influenza spread and overcoming obstacles of seasonality**

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Sponsored by



### Thursday April 21, 2022 Influenza and Respiratory Vaccines, Day 3

**9:00 Chair's opening remarks**

**Dr Jon Heinrichs, Associate Vice President, Global Project Head, Sanofi Pasteur**

#### RSV & Respiratory Infections Strategy & Control

**9:10 Nirsevimab, a monoclonal antibody for protection of all infants from RSV**

**Dr Jon Heinrichs, Associate Vice President, Global Project Head, Sanofi Pasteur**

**9:25 Current developments towards RSV vaccine**

**Dr Christy Comeaux, Medical Lead, Janssen**

9:40 Title TBC

**Senior representative, CODEX DNA**

**10:10 Current development of intranasal live attenuated vaccines for RSV and COVID-19**

**Sybil Tasker MD, MPH, FIDSA Chief Medical Officer, Codagenix**

**10:25 A nose for vaccines**

**Jan Groen, CEO, Intravacc**

10:40 Networking Coffee Break

**11:30 Development of a Novel mRNA Pertussis Vaccine**

**Dr Heath Damron, Director, West Virginia University Vaccine Development**

**11:45 Current developments toward MVA-BN-RSV vaccine**

**Peter Costa, U.S. Medical Affairs Regional Lead, Bavarian Nordic**

**12:00 A universal pneumococcal vaccine for broad pneumococcal infections and other infections**

**Dr Don Chen, President & CEO, SynAm**

12:30 Networking Lunch & Poster Session

Plenary sessions resume at 1:30 – don't miss it!

# WORLDVACCINE CONGRESS | EMERGING & RE-EMERGING

Wednesday April 20, 2022 Emerging and Re-Emerging diseases, Day 2

9:00 Chair's opening remarks

**Dr David B. Weiner**, Executive Vice President, The Wistar Institute Director, Vaccine & Immunotherapy Center Professor & WW Smith Chair in Cancer Research Professor Emeritus, **University of Pennsylvania - SOM The Wistar Institute**

## Global Health Preparedness Strategy

9:10 Expanding Zaire Ebola virus vaccine knowledge base:

- Updates on durability of immunogenicity and correlates of protection analysis
- Deeper understanding of vaccine use in Pediatric populations
- Accumulating evidence of effectiveness as tool in outbreak response
- Stockpiling approaches to support public health response readiness

**Dr Beth-Ann Collier**, Executive Director, Global Clinical Development, **Merck**

9:40 Panel Dengue – Aedes transmitted viral diseases that can cause explosive epidemic

**Moderator: Dr Duane Gubler**, Emeritus Professor, Programme in Emerging Infectious Diseases, **Duke-NUS Medical School**

**Dr Anna Durbin**, Professor, International Health, **Johns Hopkins Bloomberg School of Public Health**

**Dr Beth-Ann Collier**, Executive Director, Global Clinical Development, Vaccines, **Merck**

**Dr Eng Eong Ooi**, Professor in Emerging Infectious Diseases, **Duke-NUS Medical School**

**Dr Shibadas Biswal**, Senior Medical Director, **Takeda**

10:40 Networking Coffee Break

11:40 Late arresting replication competent bioreactor-produced PfSPZ to protect against malaria and treat chronic liver diseases

- Human monoclonal antibodies development to prevent Malaria
- Engineering Malaria sporozites as carriers of foreign molecules to immunize against 5 separate infectious diseases

**Dr Stephen Hoffman**, CEO, **Sanaria**

12:10 mRNA: A New Frontier in Vaccines and Medicines

**Martina Kovac**, MD GPD Vaccines, **PPD, part of Thermo Fisher Scientific**

12:40 Janssen's Zika vaccine developments and new data

**Dr Jenny Hendriks**, Head Department of Viral Vaccines Biomarker, **Janssen**

1:10 Networking Lunch & Poster Session

## Planning for future infectious diseases

2:40 Safety and Long-Term Immunogenicity of a Chikungunya Virus-Like Particle (CHIKV VLP) Vaccine

**James McCarty**, Consultant, **Emergent BioSolutions**

3:10 Platform technologies to address emerging infections – Lessons learned from Lassa fever program

- Phase 1 Lassa Fever trial data and safety and immunogenicity updates

**Dr Swati Gupta**, Vice President and Head of Emerging Infectious Diseases and Scientific Strategy, **IAVI**

3:25 Virus-like particle (VLP) and recombinant nanoparticle technology in fighting against Polio and Measles

**Dr Kutub Mahmood**, Project Director, **PATH**

3:55 Sci-B-Vac: results on Ph3 Hep B vaccine

**Dr Francisco Diaz-Mitoma**, CMO, **VBI Vaccines**

4:10 Networking Coffee Break – Sponsored by Croda

**CRODA**

4:40 TBC

# WORLDVACCINE CONGRESS | EMERGING & RE-EMERGING

5:10 **Role of hepatitis B vaccines in elimination of hepatitis B disease in the U.S. by 2030**

**Trisha Novy**, VP Medical Affairs, **Dynavax Technologies**

5:25 **HBsAg loss and transaminase flares: therapeutic implications for functional cure of HBV**

**Dr Andrew Vaillant**, CSO, **Replacor Inc**

5:40 **Structure based vaccine design for emerging infectious diseases**

**Dr Nelson Michael**, Director, **Centre for Infectious Diseases Research, Walter Reed Army Institute of Research**

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Sponsored by



## Thursday April 21, 2022 Emerging and Infectious Diseases, Day 3

9:00 **Chair's opening remarks**

**Dr Mark R. Schleiss**, Professor, Department of Pediatrics, Division of Infectious Diseases and Immunology, **Minnesota Medical School and Masonic Children's Hospital**

### Vaccine Pipeline Updates of Highly Infectious Diseases

9:10 **Panel: Current state of CMV vaccine development**

*Moderator:* **Dr Mark R. Schleiss**, Professor, Department of Pediatrics, Division of Infectious Diseases and Immunology, **Minnesota Medical School and Masonic Children's Hospital**

**Marianne Leruez-Ville**, Consultant Epidemiology, **Paris Descartes Université**

**Dr Stanley Plotkin**, Emeritus Professor, **University of Pennsylvania School of Medicine & Vaxconsult**

**Kevin Russell**, Associate Vice President, Clinical Research Vaccines, **Merck Research Laboratories**

**Lori Panther**, VP, Clinical Development, Infectious Diseases, **Moderna**

**Kirsten Schneider-Ohrum**, Vaccine Development Leader– CMV, **GSK Vaccines**

10:10 **Explosion in vaccines for vector borne diseases since the pandemic – How adoption of new technologies have accelerated usage**

- Current updates in DenVaxia rollout in central America to combat Dengue outbreak
- Issues of vaccine hesitancy/acceptance in central and south america

**Dr Grayson C. Brown**, Executive Director, **Puerto Rico Vector Control Unit**

**Dr Gabriella Paz-Bailey**, Lead Epidemiologist, Chief of CDC Dengue Branch, **CDC/DDID/NCEZID/DVBD**

10:40 Networking Coffee Break

11:30 **Development of enteroviral vaccines using Vero cell platform technology**

**Dinja Oosterhoff**, Director Translational Research and Innovation, **Intravacc**

11:45 **Novel native antigens stabilization approach for vaccines: Case study of Chikungunya**

**Vincent Corvest**, Senior Scientist & Business Manager, **Calixar**

12:00 **Vaccine development towards Chikungunya**

**Dr Sushant Sahastrabuddhe**, Director, Enteric Fever, **International Vaccine Institute**

12:15 **Current development towards a Shigella Vaccine candidate**

-Phase 1 clinical trials data

**Calman MacLennan**, Senior Program Officer, **Bill & Melinda Gates Foundation**

12:30 Networking Lunch & Poster Session

Plenary sessions resume at 1:30 – don't miss it!

# WORLDVACCINE

CONGRESS | CLINICAL TRIALS

# WORLDVACCINE

## CONGRESS | CLINICAL TRIALS

Wednesday April 20, 2022 Vaccines Clinical Development and Trials Conference Day 2

9:00 Chair's opening remarks

**Dr Brett Leav**, Head, Clinical Development, Public Health Vaccines, Moderna

### Conducting Vaccine Trials During a Pandemic

9:10 Use of real-world evidence for vaccine efficacy – a reflection on COVID's mass vaccination campaign

- Effectiveness (not efficacy) measured in real world
- How has COVID vaccines changed severe disease and hospitalization, transmission and infectiousness?

**Dr Jerome Kim**, Director General, IVI

9:40 Insights from the world's first COVID-19 human challenge study on young adults

**Senior representative**, hVivo

10:10 What do we understand about the Correlates of Protection (CoPs) for COVID?

**Dr Richard A. Koup, M.D.**, Chief, Immunology Laboratory, Deputy Director, VRC, NIAID, NIH

10:40 Networking Coffee Break

11:40 Reagent characterization and lot to lot control for clinical viral neutralization assays

**Dr Luc Gagnon**, Vice President, Vaccine Sciences, Nexelis

12:10 Preparing and prevention of future outbreaks in COVID-19 and other infectious diseases

- Will covid circulate seasonally like influenza, respiratory syncytial virus (RSV) and others?

**Shelley McLendon** Vice President, Project Management, Infectious Diseases, Vaccines, ICON Plc

12.40 Pandemic Preparedness: A CRO Perspective and Lessons Learned

- The role of digital and decentralized clinical trial innovations
- The adaptations needed to maintain continuity of exiting trials and initiate new trials
- The rapid deployment of vaccine and therapeutic trials to directly address the pandemic pathogen
- The importance of proactive development, validation and deployment of specialized laboratory assays

**Vanessa N. Elharrar MD, MPH**, Vice President, Vaccines Business Strategy Lead, PPD, part of Thermo Fisher Scientific

1:10 Networking Lunch & Poster Session

2:40 Specificity and Utility of Elispot in Vaccine Clinical Testing

**Dr Thomas Beadnell, PhD**, Scientific Manager, Eurofins Viracor BioPharma Services

2:55 Overcoming challenges in seasonal vaccine studies – title TBC

**Dr William Smith**, Alliance for Multispecialty Research

3:10 Challenges in antiviral/vaccine development for respiratory viruses during possible future pandemics

**Dr Jelle Klein**, Associate Medical Director CPU, SGS Health Science

**Dirk Roymans**, Managing Director, DNS Life Sciences Consulting

3:40 Impact of pre-existing immunity on the outcome of vector-based vaccine and gene therapy clinical trials:

Evolution of delivery-vector viral neutralization assays

**Bob Bailer**, Senior Director, Vaccines Laboratory, Q<sup>2</sup> Solutions

3:55 Leveraging Central Laboratory Scientific Expertise with Operational Agility to Deliver Clinical Trials at Scale - Examples from the Pandemic

**Vincent Drouillon, PharmD, Clin.Bio.**, VP, Global Laboratory Operations and Medical Affairs, Labcorp Drug Development

4:10 Networking Coffee Break – Sponsored by Croda

# CRODA

# WORLDVACCINE

CONGRESS | CLINICAL TRIALS

4:40 **Regulatory Insights in COVID Vaccine Development**

**Antonina Nikolova**, Senior Director, CMC, **CATO SMS – Pharm-Olam**

5:10 **Vaccines clinical trials in Latin America, making the impossible possible**

**Jose Jimeno**, CEO & **Paula Casasco**, Quality & Training Director, **Vaxtrials**

5:25 **Title TBC - Matrix**

5:40 **Title TBC**

**Senior representative, Ligand**

5:55 **Regulatory learnings from the pandemic – can we sustainably maintain this momentum?**

**Javier Diez-Domingo**, Head of the Vaccine Research Department, **Pratia**

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Sponsored by



# WORLDVACCINE

## CONGRESS | BIOPROCESSING MANUFACTURING

Official Manufacturing Partner



Wednesday April 20, 2022 Vaccine Bioprocessing & Manufacturing Conference, Day 2

9:00 Chair's opening remarks

**Dr Dirk Redlich**, Vice President, Head CMC Development and Clinical Trial Material (CTM) Manufacturing, **Janssen Vaccines**

### Vaccine Bioprocessing Trends and Challenges

09:05 **Lessons learned and being learned from pandemic vaccine manufacturing**

- What does a long-term manufacturing road map look like?
- Identifying global manufacturing capacity and capability
- How to build a global network of facilities and hubs for more sustainable vaccine manufacturing and delivery
- How to establish regional health security

**Dr Martin Friede**, Coordinator, Initiative for Vaccine Research (IVR), **WHO**

**Dr Matthew Downham**, Director, Manufacturing & Supply Chain Networks, **CEPI**

**Vivian Hsu**, Deputy Director Strategy Planning and Management, Vaccine Development & Surveillance, **BMGF**

**Simone Blayer**, Global Head, CMC, **PATH**

**Rajinder Suri**, CEO, **DCVMN**

09:55 **Unique rapid production opportunities and challenges that face RNA delivery and manufacture**

- How low of a dose can go to stretch vaccine availability?
- What kind of delivery routes can be used with next generation RNA vaccines? Patches, orally administrated, devices?
- Stabilization of mRNA products
- Can RNA vaccines be manufactured and transported cheap enough for global health purposes?
- Challenges with analytical characterization and rapid lot release of multivalent mRNA vaccines
- How will the expansion mRNA into other prophylactic vaccines change the bioprocessing and manufacture considerations?

**Dr Gautam Sanyal**, Principal Consultant and Founder, **Vaccine Analytics, LLC**

**Dr Philippe-Alexandre Gilbert**, Senior Program Officer CMC, **Bill & Melinda Gates Foundation**

*Followed by Q&As*

10:40 Networking Coffee Break

### Vaccine Development Processes & Global Health

11:40 **Enabling Global Access to Analytical Tools to Ensure Quality of mRNA and Viral Vector Vaccines**

**Dr Diane McCarthy**, Director, Biologics Pipeline Development, **USP Global Biologics**

11:55 **Identity, Quantity, and Integrity Characterization of Multivalent Vaccines from Bioprocess to Release**

**April Blodgett**, Regional Sales Director, **IndevR**

12:10 **A Case Study on the Method Development Lifecycle of a rVSV-based Vaccine**

**Ellen Lawrence**, Senior Director, Analytical Development, **Emergent BioSolutions**

12:40 **mRNA manufacturing: removing bottlenecks in PD and manufacturing process**

**Dr Piergiuseppe Nestola**, Global Vaccines Technology Consultant, **Sartorius Stedim Biotech**

1:10 Networking Lunch & Poster Session

2:40 **A case study on the collaboration between MilliporeSigma, Technovax and Innovative Biotech to develop, manufacture and deliver a VLP-based vaccine platform to West African nations**

# WORLDVACCINE

## CONGRESS | BIOPROCESSING MANUFACTURING

**Dr Claire Scanlan**, Process Development Scientist (PDS) & Manager, East Coast PDS region, Technical and Scientific Solutions (TSS) Group, **Merck Millipore**

3:10 **Current application and development of novel adenovirus vectored vaccines**

**Dr Peter Abbink**, Head of R&D - Director of Operations, **Batavia Biosciences**

3:25 **Biophysical Toolbox To Predict and Assess the Stability of 3rd Generation Vaccines**

- Using light scattering to characterize LNPs and liposomes, including vaccines

**Ronald Soriano**, Field Application Scientist, **Malvern**

3:40 **Stopper migration in frozen pre-filled syringes**

**Dr Zane Baird**, Research Scientist, **Baxter**

3:55 **Formulations to stabilize vaccines during manufacturing, storage and logistics – concept and case studies**

**Dr Sabine Hauck**, SVP Corporate Development, **Leukocare**

4:10 **Networking Coffee Break – Sponsored by Croda**

# CRODA

### Improving Vaccine Uptake with Innovative Delivery Platforms

4:40 **Logistics, last-mile, and innovations to ensure successful deployment of next-generation COVID-19 vaccines**

**David Hipkiss**, CEO **Enesi Pharma**

4:55 **Status on the development of Cationic Adjuvant Formulation CAF**

**Dr Dennis Christensen**, Head of Vaccine Adjuvant Research, Center for Vaccine Research, **Statens Serum Institut**

5:10 **Alternative delivery system technology showcase**

**Carmen Ledesma-Feliciano**, Clinical Device Specialist at **PharmaJet**, **Pharmajet**

5:25 **Biophysical characterization, PAT, and quality control of vaccines via light scattering**

**William Penny**, Regional Account Manager & Application Scientist, **Wyatt Technology Corp.**

5:55 **How do different routes of delivery influence the immunological outcome?**

**Ted Hibben**, CBO, **Vaxess Technologies, Inc.**

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Sponsored by



### Thursday April 21, 2022 Vaccine Bioprocessing & Manufacturing Conference, Day 3

9:00 Chair's opening remarks

**Dr Dirk Redlich**, Vice President, Head CMC Development and Clinical Trial Material (CTM) Manufacturing, **Janssen Vaccines**

### Manufacturing Innovations – Pushing New Boundaries

9:10 **Gene therapy platform optimization- insights from a CDMO**

**Dr Sneha Rangarajan**, Senior Scientist PD, **IDT-Biologika**

9.40 **High-speed, Aseptic Manufacturing of a High-Density, Microneedle Array Patch (HD-MAP)**

**Tom Lake**, SVP, Strategic Alliances & Commercialization, **Vaxxas**

# WORLDVACCINE

## CONGRESS | BIOPROCESSING MANUFACTURING

9:55 **Title TBC**

[Dr Alex Koglin, NtxBio](#)

10:10 **MAPs featuring ceramic nano pores that boost vaccine delivery**

[Mike G.W. de Leeuw, CEO, Mylife Technologies](#)

10:25 **Manufacturing Innovations-Pushing New Boundaries**

[Mark Emalfarb, Chief Executive Officer, Dyadic](#)

10:40 Networking Coffee Break

11:30 **A digital twin for Vaccine adjuvant**

- Using the “digital twin” process to fine tune vaccine production
- Continual process, mirror processing into a digital world
- How does the digital twin work and react within specification

[Sandrine Dessoy, GSK vaccines](#)

[Laurent Strodiot, GSK vaccines](#)

12:00 **Integrated and Aligned End-to-End Vector and Cell Therapy Production: Charles River C&GT 360° Portfolio**

- Charles River is building a comprehensive portfolio of integrated services from early discovery to clinical and commercial C&GT manufacturing.
- We will present on our integrated and aligned C&GT development and manufacturing services, profiling key strategic partnerships that augment the service offering.

[Daniel Smith, Executive Director, Global Cell & Gene Therapy Portfolio Strategy, Cobra Biologics: A Charles River Company](#)

12:30 Networking Lunch & Poster Session  
Plenary sessions resume at 1:30 – don’t miss it!

# WORLDVACCINE

## CONGRESS | VETERINARY

Wednesday April 20, 2022 Veterinary Vaccines Conference, Day 2

9:00 Chair's opening remarks

**Dr Cyril Gay**, Senior National Program Leader, Office of National Programs, **USDA**

### SARS-CoV-2 in Animals

9:10 The many hosts of SARS-CoV-2: Should we be concerned about the cross species spread?

**Dr Vivek Kapur**, Professor of Microbiology and Infectious Diseases, Huck Distinguished Chair in Global Health, **Penn State**

9:40 Is there a demand/ need for SARS-CoV-2 vaccines for animals?

- Tackling SARS-CoV-2 in animals, where are we at?
- What criteria do we need for SARS-CoV-2 animal vaccines in the U.S., e.g. companion animals, white tail deer?

**Dr John A. Korslund**, SARS-Cov-2 Coordinator, Office of Interagency Coordination, Strategy and Policy, Veterinary Services, APHIS, **USDA**

10:10 Update on the Zoetis SARS-CoV-2 vaccine

- How well has the vaccine worked in the field?

**Dr Mahesh Kumar**, SVP, Global Biologics R&D, **Zoetis**

10:40 Networking Coffee Break

### One Health: Future Pandemic Preparedness

11:40 Panel: Using lessons learned from the pandemic to be better prepared for future pandemics

- Addressing the threat of zoonotic diseases
- Collaboration and the important role of research labs working with public health and policy makers
- The importance of information sharing and disease surveillance

Moderator: **Dr Cyril Gay**, Senior National Program Leader, Office of National Programs, **USDA**

**Dr Volker Gerdts**, Director & CEO, **VIDO**

**Col Deborah Whitmer**, Chief of Staff, **U.S. Army Medical Research and Development Command**

**Dr Lisa Hensley**, Associate Director of Science at the Office of the Chief Scientist, Integrated Research Facility, **NIH**

**Dr Heather Allen**, Chief, National Security Division, **USDA Office of Homeland Security**

**Dr Andrew Kilanski**, Senior Director, Emerging Infectious Diseases, **IAVI**

12:25 Panel: Scientific hurdles in developing vaccines for emerging and transboundary diseases of livestock

- Ensuring the development and availability of vaccine platforms for emergency response

Moderator: **Dr Cyril Gay**, Senior National Program Leader, Office of National Programs, **USDA**

**Professor Jürgen A. Richt**, Director, Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), **Kansas State University**

**Dr Alan Young**, Chief Technology Officer (CTO), **Medgene Labs**

**Dr Mahesh Kumar**, SVP, Global Biologics R&D, **Zoetis**

1:10 Networking Lunch & Poster Session

2:40 Panel: One Health perspective: The potential of microbiota-targeted interventions to optimize immunity and vaccine effectiveness

Moderator: **Scott Holmstrom**, Senior Vice President, Research & Development, **United Animal Health**

**Jennifer Filbey**, Chief Executive Officer, **Mazen Animal Health**

**Rachelle Galvin**, Chief Operating Officer, **Resilient Biotics**

**Dr Sherry Layton**, Chief Scientific Officer, **Vetanco**

3:25 Using zoonotic disease surveillance to guide oral vaccine design

**Dr Jolieke G. van Oosterwijk**, Chief Scientific Officer, **US Biologic Inc.**

# WORLDVACCINE CONGRESS | VETERINARY

3:40 Progress in the development of effective vaccines against the pandemic strain of African Swine Fever  
[Dr Douglas Gladue](#), Senior Scientist, Plum Island Animal Disease Center, [USDA](#)

4:10 Networking Coffee Break – Sponsored by Croda

## CRODA

4:40 Targeting a global health problem: Vaccine design and challenges for the control of tick-borne diseases  
[Dr Suman Mahan](#), Research Director, [Zoetis](#)

5:10 Panel: What are the risks to self-spreading viruses?

- The need for biosafety and international standards
- Emerging diseases from wildlife
- Applications in human vaccines

Moderator: [Dr Cyril Gay](#), Senior National Program Leader, [Office of National Programs, USDA](#)

[Charles E. Rupprecht](#), Director, [LYSSA LLC](#)

[Dr Camille Hopkins](#), Wildlife Disease Coordinator, [USGS Ecosystems Mission Area](#)

[Dr Stanley Plotkin](#), Emeritus Professor, [University of Pennsylvania School of Medicine & Vaxconsult](#)

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Sponsored by



# WORLDVACCINE

## CONGRESS | PARTNERSHIPS

Thursday April 21, 2022 Vaccine Partnerships Conference Day 3

### A Deep Dive into Successful Partnering, Funding and Knowledge Sharing

9:00 Morning Chair's Opening Remarks

**Michael Salgaller**, Supervisor, Invention Development and Marketing Unit, **NIH**

9:10 How do we incentivise industry to continue to make infectious disease vaccines with unclear commercial potential?

- How we make this sustainable pre and post pandemic?
- Where are the largest costs and biggest risks? (R&D, trials, manufacturing)
- How to secure vaccine funding for non commercial vaccines
- Will funding dry up post pandemic?
- How to attract a strategic partnership? Is that the only viable option?

**Moderator: Hansilla Alaigh**, Senior Director, Vaccine Global Program, **Clover Biopharmaceuticals**

**Francesco Berlanda Scorza**, Director, Vaccines Global Health, **GSK**

**Dr Tim Cooke**, Biotechnology Industry Representative, National Vaccine Advisory Committee, **US HHS**

**Dr Michel De Baar**, Executive Director, Business Development & Licensing, Europe, **Merck**

**Dr Kimberly L. Taylor**, Senior Scientific Officer, Concept Acceleration Program – Vaccines, **NIH**

**Casey Selywyn**, Special initiatives Lead & Senior Officer, **BMGF**

9:55 Achieving Success by Leveraging Federal Labs as Technology Development and Commercialization Partners

**Moderator: Michael Salgaller**, Supervisor, Invention Development and Marketing Unit, **NIH**

**Barry Datlof**, Chief, Business Development and Commercialization, **U.S. Army Medical Research and Development Command**

**Paul Zielinski**, Executive Director, **Federal Laboratory Consortium for Technology**

**Steven M. Ferguson**, Special Advisor, NIH Office of Technology Transfer, **NIH**

10:40 Networking Coffee Break

11:30 Innovating health care by accelerating life science start-ups through strategic advice and financing

- Collaborating with 3rd parties and creating strategic partnerships in vaccine development (JLABS)

**Stephen Auvil**, Chief Program Operations Officer, **Tedco**

**Sally Allain**, Head, JLABS, **Johnson & Johnson Innovation**

12:00 The role of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership in supporting successful vaccine development

**Dr Michael Santos**, Vice President, Science, **Foundation for the National Institutes of Health**

12:30 Networking Lunch & Poster Session

Plenary sessions resume at 1:30 – don't miss it!

# WORLDVACCINE

## CONGRESS | VACCINE SAFETY

Wednesday April 20<sup>th</sup>, 2022 Vaccine Safety - Conference Day 2

9:00 Chair's opening remarks: [Dr Walter Straus](#), Vice-President, Clinical Safety Lead, [Moderna Therapeutics](#)

### Keynote

09:10 Panel: **How have we made progress in the fight against scientific misinformation?**

- To what extent has vaccine disinformation hindered our response to the pandemic?
- What strategies are showing to be the best way to fight anti-vaxxer and anti-science misinformation and disinformation online, in the media, and our communities?
- How do we shift the needle and reach people sitting on the fence and those who lack easier access to vaccines?
- Have/will public health organizations begin to challenge the "super spreaders" of disinformation on their communication platforms, particularly in the comments sections?
- What strategic, cross-sector coalitions have been formed to combat scientific and specifically vaccine misinformation/disinformation?

**Moderator:** [Dr Michael Miller](#), Health Care & Life Sciences Consultant and Advisor, [HealthPolCom](#)

[Dr Peter Hotez](#), Dean, [National School of Tropical Medicine](#)

[Dr Rupali Limaye](#), Director of Behavioral and Implementation Science, [International Vaccine Access Center](#), Associate Director for Behavioral Research, [Institute for Vaccine Safety, JHU](#)

[Dr Hussain Lalani](#), Co-Founder, [ThisIsOurShot – VacunateYa](#); Primary Care Doctor, [Brigham and Women's Hospital](#)

[Dr David A. Broniatowski](#), Director, Decision Making and Systems Architecture Laboratory, [George Washington University](#)

### Evolution of vaccine safety during COVID-19

10:10 Development and review of VSAFE during COVID-19

[Dr Tanya Myers](#), Epidemiologist, Co-Lead – V-Safe, [CDC](#)

### 10:40 Networking Coffee Break

11:40 The Brighton Collaboration's BRAVATO (Benefit-Risk Assessment of VAccines by TechnOLogy) Vaccine Templates

[Dr Sonali Kochhar](#), MD, Clinical Associate Professor, Department of Global Health, [University of Washington](#)

[Dr Bennett Levitan](#), Senior Director, Benefit-Risk Assessment, Global Epidemiology, [Janssen Research & Development](#)

12:10 Panel: **Monitoring COVID-19 Vaccine Safety under Emergency Use Authorization: Challenges and Lessons?**

- How well did federal reporting systems work?
- How valuable were monthly PSUR reports?
- What were the burdens placed upon the stakeholders? How do we titrate the need to monitor safety with appropriate resourcing?
- Lessons in regulatory reporting during pandemic that can be carried over to future pandemics – how long will this level of reporting continue?

**Moderator:** [Dr Walter Straus](#), Vice-President, Clinical Safety Lead, [Moderna Therapeutics](#)

[Dr Kourtney Davis](#), Vice President, Global Epidemiology, [Janssen R&D](#)

[Dr Jamie Wilkins](#), Head- Risk Management Center of Excellence- Worldwide Safety, [Pfizer](#)

[Dr Narayan Nair](#), Director, Division of Epidemiology, [FDA](#)

[Dr Denny Kim](#), SVP, Chief Safety Officer, [Novavax](#)

### 1:10 Networking Lunch & Poster Session

2:40 The role of epidemiologists in communicating SARS-CoV-2 evidence: a call for adopting standards

[Dr Priya Bahri](#), Principal Scientific Officer, Human Medicines, Quality & Safety of Medicines, Pharmacovigilance, [European Medicines Agency](#)

### Vaccine Safety Surveillance

# WORLDVACCINE CONGRESS | VACCINE SAFETY

## 3:10 Panel: Advancing benefit/risk assessment for vaccines in LMICs

- Choice of vaccines
  - 1 dose series or vaccines that require 2 doses?
  - Choosing intervals between 2 dose vaccines how best to allocate rare resources?
  - Level of protection vs durability
- Assessing the risk in mass vaccination campaigns without good AE reporting (anaphylaxis, TTS, etc.)

**Moderator: Dr Alexander Precioso**, Director, Clinical Safety and Risk Management Center, **Instituto Butantan**  
**Dr Anna Durbin**, Director, Center for Immunization Research, **Johns Hopkins Bloomberg School of Public Health**  
**Dr Hector Izurieta**, Associate Director for Novel Clinical Investigations, **Office of Vaccine Research and Review (OVR)**, CBER, FDA

*Invited: Ashley Wivel, Vice President, Head of Clinical Safety and Risk Management, Merck*

*Invited: Gustavo Mendes Lima Santos, General Manager of Medicines and Biological Products, ANVISA*

## 4:10 Networking Coffee Break – Sponsored by Croda

# CRODA

## 4:40 Novel methods in vaccine safety surveillance for detecting rare adverse events in special populations

*Invited: Dr Steven Black, Adjunct Professor, UC Department of Pediatrics, Cincinnati Children's*

## 5:10 Butantan PV program - linking different registries with postvaccine adverse events

**Maria Beatriz Lucchesi**, Pharmacovigilance manager, **Instituto Butantan**

## 5:40 Linking immunization registries to outcomes in pregnancy

**Dr Deshayne Fell**, Associate Professor, School of Epidemiology and Public Health, **University of Ottawa**

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Sponsored by



## Thursday April 21<sup>st</sup>, 2022 - Vaccine Safety - Conference Day 3

9:00 Chair's opening remarks: *Invited: Vince Blaser, Director, Advocacy and Outreach, Vaccine Acceptance and Demand, Sabin Vaccine Institute*

### Combatting Hesitancy & Improving Uptake

## 9:10 Identifying & using specific predictors of vaccine hesitancy amongst healthcare workers

**Dr Anthony Baffoe-Bonnie**, Carilion Clinic Associate Professor of Medicine, VTCOM; Infectious Diseases Division, Medical Director of Infection Control,, **Virginia Tech**

**Jesse Bendetson**, MD Candidate, **Virginia Tech Carilion School of Medicine**

**Mandy Swann**, **Virginia Tech Carilion School of Medicine**

## 9:40 Vaccine Mandates vs Trust

**Prof Brian Dean Abramson, Esq., LL.M.**, Author, Vaccine, Vaccination, and Immunization Law, **Bloomberg Law**

# WORLDVACCINE

## CONGRESS | VACCINE SAFETY

10:10 Vaccine misinformation in the era of COVID-19

**Dr David A. Broniatowski**, Director, Decision Making and Systems Architecture Laboratory, **George Washington University**

10:40 Networking Coffee Break

11:30 Addressing health inequities & mistrust in communities of color; what have we learnt?

**Dr Cynthia A. Gomez**, Professor Emeritus, **San Francisco State University, University of California, San Francisco**

12:00 Vaccine communication, using social media as a platform that enhances scientific sharing

**Amy Pisani**, CEO, **Vaccinate Your Family**

12:30 Networking Lunch & Poster Session

Plenary sessions resume at 1:30 – don't miss it!

# WORLDVACCINE CONGRESS | SUPPLY & LOGISTICS

Official Logistics Partner



## DP WORLD

Wednesday April 20, 2022 Vaccine Supply & Logistics Conference Day 2

9:00 Chair's opening remarks:

9:10 **Overcoming supply chain challenges in emergency response situations**  
**Mike Bhaskaran**, Chief Operating Officer of Logistics & Technology, **DP World**

### Clinical Trial Logistics

9:40 **Vaccination data transfer from clinical trials into an immunization information system**  
**Rebecca Coyle**, Executive Director, **American Immunization Registry Association (AIRA)**

10:10 **Vaccinating the Globe**  
**Dan Bell**, Senior VP, Americas Region, **Marken**

10:40 Networking Coffee Break

### Key Material Supply & Planning

11:40 **Establishing and maintaining a stability budget for a successful vaccine supply chain**  
**Rebecca Gentile**, Associate Director, **Merck**

12:10 **Avoiding key material bottlenecks with improved regulatory strategies**  
**Charles Kline**, Distinguished scientist, CMC Regulatory Affairs Vaccines, **Merck**

12:40 **Global Vaccine Supply and Demand: The Post-Pandemic Equilibrium**  
**Dr Matt Linley**, Lead Analyst, **Airfinity**

1:10 Networking Lunch & Poster Session

### Technology & Cold Chain

2:40 **Active shipper solution for ultra cold temperature vaccines**  
**John McNally**, Cold Chain lead for Large Molecules, **Johnson & Johnson**  
**Mohit Chopra**, COVID-19 Vaccine Project Lead, **Johnson & Johnson**

2:55 **Land Cruiser–The first WHO-prequalified refrigerated vehicle for vaccine distribution**  
**Yoshinobu Nagamine**, Senior Donor Manager, **GAVI**

3:10 **Panel: The importance of cold/ultra-cold chain analysis in temperature-sensitive vaccines in LMIC**

- How do we ensure a cold chain is running as efficiently as possible?
- How do we prepare a country for increased demand in cold chain availability?
- What advantages does cold chain modelling during a pandemic have and what has it taught us?
- How do we design a cold chain for a LMIC that is sustainable financially and ready for a surge in demand when needed?

Invited: Moderator: Dana Dallas, Cold Chain & Vaccine Programme Manager, Defence Logistics Agency  
**Darin Zehrung**, Global Program Leader, Medical Devices and Health Technologies, **PATH**  
**Mohit Chopra**, COVID-19 Vaccine Project Lead, **Johnson & Johnson**  
**Thomas Sorensen**, Senior Manager, Cold Chain, Supply Division, **UNICEF**  
**Alexander Doxiadis**, Associate Director Cold Chain and Logistics for Vaccine, **CHAI**

# WORLDVACCINE

## CONGRESS | SUPPLY & LOGISTICS

4:10 Networking Coffee Break – Sponsored by Croda

## CRODA

### Vaccine Distribution

4:40 Accessibility and Agility in Clinical supply Chains

**Marc van Puijssen**, General Manager Viroclinics Xellerate, **Viroclinics-DDL**

5:10 Protecting a vaccine supply chain against analogue cybersecurity threats

**Dr Kevin Fu**, Associate Professor, Electrical Engineering and Computer Science, **University of Michigan**

5:40 Streamlining vaccine supply—Manufacturer and supplier marketplace platform

**Matthew Downham**, Director, Manufacturing & Supply Chain Networks, **CEPI**

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team  
Sponsored by

### Thursday April 21, 2022 Vaccine Supply & Logistics Conference Day 3

9:00 Chair's opening remarks: **Col. Anthony Bostick**, Head Vaccine Operations, **Defence Logistics Agency**

### Supply during outbreaks & Last mile delivery

9:10 Maintaining routine immunization programs during a global pandemic

**Lora Shimp**, Technical Director, Immunization Center, **John Snow Inc.**

9:40 A Novel Platform to Visualize and Monitor the System of Vaccination for Hard-to-Reach Populations

**Patrick Wedlock**, Global Health Program Lead, **System Inc.**

10:10 Drone vaccine delivery for remote locations

*Reserved: Senior Representative, Wingcopter*

10:25 Supporting Equitable Global Vaccine Distribution To Save Lives and Protect Investments

**Souleymane Sawadogo**, Vice President of Global Health, **Parsyl**

10:40 Networking Coffee Break

11:30 Panel: Ensuring equitable vaccine distribution—An impossible task?

- What has the pandemic taught us with regards to vaccine equity?
- What is the argument for wavering Trade Related Aspects of Intellectual Property Rights (TRIPS)?
- How do we establish a line between profitable products for the industry and access for LMICs?
- What are the knock-on effects of vaccine mandates on vaccine equity?

**Moderator: Dr Karin Bok**, Director of Pandemic Preparedness and Emergency Response, **NIAD Vaccine Research Center**

**Jenny Ottenhoff**, Senior Policy Director of Global Health, **The ONE Campaign**

**Javier Guzman**, Director of Global Health Policy, **Centre of Global Development**

**Dr Elvin Geng**, Professor Medicine, Division of Infectious Diseases, **Washington University St. Louis**

**Dr Maria Elena Bottazzi**, Associate Dean, National School of Tropical Medicine & Co-Section Head, **Paediatric Tropical Medicine**

12:30 Networking Lunch & Poster Session  
Plenary sessions resume at 1:30 – don't miss it!

9:00 Chair's opening remarks

### Vaccine Markets, Public Health & Policy

9:10 Panel: How can we build a more resilient public health infrastructure for vaccines?

- What has the pandemic taught us about how to maintain a healthy market for vaccines
  - Balance across supply- and demand-side factors
  - Demand – investment in vaccination – how is it hindered? How can we better evaluate the full societal value of vaccination?
  - Supply – what are the challenges and risks on the supply side of vaccine markets how can supply-side stakeholders create supply-chain resiliency – what are the knock-on effects of market shaping activities at regional or global levels? How can we make sure systems can do what they need to when asked to surge?
- What changes need to take place in the vaccine ecosystem to ensure better preparation and response – what will these changes mean for routine immunization?
- Who are the stakeholders driving markets –
  - what are the dynamics governing healthy markets/ e.g. different geographies / different regulatory requirements etc.?
- Are we better at understanding downstream impacts of individual market shaping activities? What have we learnt during the pandemic?
- How can frameworks be used to anticipate market shortcomings and provide sustainable interventions at the systems level?

**Harry Brady**, Executive Director, International Vaccines Public Policy, MSD

**Adrian Towse**, Director Emeritus and Senior Research Fellow, Office of Health Economics

*Invited: Gian Gandhi, Chief, Covid-19 Tools (Vaccines, Diagnostics, Therapeutics) and Health Emergencies, UNICEF*

10:10 Giving access to immigrant and ethnic minorities: Our strategy in administering 2 million COVID vaccines in New York – Title TBC

**Senior representative, SOMOS**

10:40 Networking Coffee Break

11:40 Data driven health advocacy to inform vaccine policy reforms

- Use of immunization data to inform vaccine policy – how can we improve the tools we have to understand data in near real-time?
- How is data being used by stakeholders to drive advocacy and catch up of routine immunization?
- How can data be used to advance policy reforms? E.g. By providing context to federal and state policymakers during ongoing public health and economic considerations?
- Can this data be used in educational settings to raise awareness on the importance of routine immunization?

**Kate Hashey**, Director, Vaccine Policy, GSK

**Abby Bownas**, Manager, Adult Vaccine Access Coalition; Partner, NVG LLC.

**Rebecca Coyle**, Executive Director, American Immunization Registry Association (AIRA)

*Invited: Lisa Coen, U.S. Public Affairs Lead, Vaccines, Pfizer*

*Additional speakers TBC*

12:40 Vaccine acceptance – Title TBC

**Jacob Braude**, Principal, Applied Behavioral Insights, ZS Associates

1:10 Networking Lunch & Poster Session

**Evolution of vaccine market access for specific populations**

**2:40 Studies informing vaccine policy in pregnancy**

**Dr Deshayne Fell**, Associate Professor, School of Epidemiology and Public Health, **University of Ottawa**

**3:10 How can we achieve optimal pediatric vaccine policy (in the context of COVID-19)?**

**Invited: Prof. Bonnie Maldonado**, Professor of Pediatrics and of Epidemiology and Population Health, Chief, Division of Pediatric Infectious Diseases, **Stanford University School of Medicine**

**3:40 Understanding impact of HIV on covid & routine immunization programs**

**4:10 Networking Coffee Break – Sponsored by Croda**

**CRODA**

**4:40 How has covid-19 informed vaccine policy in elderly populations**

**Dr Kathy Neuzil**, Professor in Vaccinology and Director, Center for Vaccine Development and Global Health **University of Maryland**

**5:10 Panel – What challenges must be addressed to accelerate adoption and funding for new vaccines?**

- COVID-19 vaccine adoption and funding much faster than the average 5-6 years for new vaccines – can we replicate speed for other new vaccines?
- How can manufacturers provide more information to help recommending bodies make quicker decisions?
  - E.g. pre-launch epidemiology studies -costly but provide more data
  - What other data can be collected pre-launch?
  - What do manufacturers need to be considering in phase 3? What information do they need to provide to aid policy decisions?
- Will recommending bodies be willing to take more risks despite all data not being available at launch?
  - E.g. length of protection, vax & pregnancy data, co-morbidities
- What is the minimum amount of data necessary to be able to recommend a vaccine?
  - How do recommendations get made when no data is available?

**Moderator: Dr Noni MacDonald**, Professor of Pediatrics, **Dalhousie University**

**Jim Wassil**, COO, **Vaxcyte**

**Dr Sonali Kochhar**, MD, Clinical Associate Professor, Department of Global Health, **University of Washington**

**Kathy Neuzil**, Professor in Vaccinology and Director, Center for Vaccine Development and Global Health, **University of Maryland**

**Norman Baylor**, former Director, Office of Vaccines Research and Review/CBER, **FDA**; Editor In Chief: Biologicals, **Journal of the International Alliance for Biological Standardization**

6:10 Chair's Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Sponsored by



# WORLDVACCINE CONGRESS WASHINGTON

April 18-21 2022

Marriott Marquis Washington  
Marquis Ballroom  
M2-Meeting Level

■ Reserved  
■ Sold

